文献速递消化系统肿瘤支持与姑息治疗

霍奇金淋巴瘤幸存者中放疗与丙卡巴肼剂量与结直肠癌风险的关联

Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma.
PubMed 文献 · JAMA Oncol · 2023-01-01

该巢式病例对照研究纳入荷兰5家医院中心1964至2000年确诊的5年霍奇金淋巴瘤幸存者,中位随访约26年,分析放疗剂量与丙卡巴肼剂量与结直肠癌风险的关联。结果显示,膈下放疗者结直肠癌发生率升高(RR 2.4),丙卡巴肼剂量>8.4 g/m2者亦升高(RR 2.5),全大肠每增加1 Gy的ERR为3.5%,且随丙卡巴肼剂量增加而增强。

要点

  • 膈下放疗与结直肠癌风险升高相关(RR 2.4,95%CI 1.4-4.1)。
  • 丙卡巴肼剂量>8.4 g/m2与结直肠癌风险升高相关(RR 2.5,95%CI 1.3-5.0)。
  • 全大肠每增加1 Gy的ERR为3.5%,且随丙卡巴肼剂量增加而增强。

核心结论

  • 在5年霍奇金淋巴瘤幸存者中,放疗与结直肠癌风险呈剂量-反应关联,且该关联受丙卡巴肼剂量修饰。

研究设计与样本

  • 巢式病例对照研究,纳入荷兰5家医院中心1964至2000年确诊的5年霍奇金淋巴瘤幸存者,诊断时年龄15至50岁,中位随访约26年。
  • 共316名参与者,其中78例发生结直肠癌(病例),238例未发生(对照),按性别、霍奇金淋巴瘤诊断年龄和诊断日期个体匹配。
  • 数据分析了2021年7月至2022年10月。

主要发现

  • 霍奇金淋巴瘤与结直肠癌诊断的中位间隔为25.7年(IQR 18.2-31.6)。
  • 接受膈下放疗者结直肠癌发生率升高(RR 2.4,95%CI 1.4-4.1)。
  • 接受丙卡巴肼剂量>8.4 g/m2者结直肠癌发生率升高(RR 2.5,95%CI 1.3-5.0)。
  • 结直肠癌发生率随全大肠平均放疗剂量和受累肠段剂量呈线性增加。
  • 未接受丙卡巴肼者全大肠每增加1 Gy的ERR为3.5%(95%CI 0.4%-12.6%),丙卡巴肼剂量每增加1 g/m2,ERR增加1.2倍(95%CI 1.1-1.3)。

临床怎么用

  • 作者认为这些发现可能有助于个体化结直肠癌风险评估、识别高危幸存者以进行后续筛查以及优化治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hodgkin lymphoma (HL) survivors have higher rates of colorectal cancer, which may be associated with subdiaphragmatic radiation therapy and/or alkylating chemotherapy. Although radiation dose-response associations with breast, lung, stomach, pancreatic, and esophageal cancer after HL have been demonstrated, the association of radiation therapy with colorectal cancer remains unclear. OBJECTIVE: To quantify the rate of colorectal cancer according to radiation dose to the large bowel and procarbazine dose among HL survivors. DESIGN, SETTING, AND PARTICIPANTS: A nested case-control study examined 5-year HL survivors at 5 hospital centers in the Netherlands. Participants had been diagnosed with HL in 1964 to 2000, when they were 15 to 50 years of age, and were followed for a median of approximately 26 years. Survivors of HL who developed colorectal cancer and survivors who were selected as controls were individually matched on sex, age at HL diagnosis, and date of HL diagnosis. Data were analyzed from July 2021 to October 2022. EXPOSURES: Mean radiation doses to the large bowel were estimated by reconstructing individual radiation therapy treatments on representative computed tomography data sets. MAIN OUTCOMES AND MEASURES: Excess rate ratios (ERRs) were modeled to evaluate the excess risk associated with each 1-gray increase in radiation dose, and potential effect modification by procarbazine was explored. RESULTS: The study population included 316 participants (mean [SD] age at HL diagnosis, 33.0 [9.8] years; 221 [69.9%] men), 78 of whom were HL survivors who developed colorectal cancer (cases) and 238 who did not (controls). The median (IQR) interval between HL and colorectal cancer was 25.7 (18.2-31.6) years. Increased colorectal cancer rates were seen for patients who received subdiaphragmatic radiation therapy (rate ratio [RR], 2.4; 95% CI, 1.4-4.1) and those who received more than 8.4 g/m2 procarbazine (RR, 2.5; 95% CI, 1.3-5.0). Overall, colorectal cancer rate increased linearly with mean radiation dose to the whole large bowel and dose to the affected bowel segment. The association between radiation dose and colorectal cancer rate became stronger with increasing procarbazine dose: the ERR per gray to the whole bowel was 3.5% (95% CI, 0.4%-12.6%) for patients who did not receive procarbazine, and increased 1.2-fold (95% CI, 1.1-1.3) for each 1-g/m2 increase in procarbazine dose. CONCLUSIONS AND RELEVANCE: This nested case-control study of 5-year HL survivors found a dose-response association between radiation therapy and colorectal cancer risk, and modification of this association by procarbazine. These findings may enable individualized colorectal cancer risk estimations, identification of high-risk survivors for subsequent screening, and optimization of treatment strategies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Geurts YM, Shakir R, Ntentas G, et al. Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma. JAMA Oncol. 2023. PMID: 36729438. doi:10.1001/jamaoncol.2022.7153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。